AU2020229558A1 - Combinational medication - Google Patents

Combinational medication Download PDF

Info

Publication number
AU2020229558A1
AU2020229558A1 AU2020229558A AU2020229558A AU2020229558A1 AU 2020229558 A1 AU2020229558 A1 AU 2020229558A1 AU 2020229558 A AU2020229558 A AU 2020229558A AU 2020229558 A AU2020229558 A AU 2020229558A AU 2020229558 A1 AU2020229558 A1 AU 2020229558A1
Authority
AU
Australia
Prior art keywords
group
substituted
combination medicine
salt
hydrogen atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020229558A
Other languages
English (en)
Inventor
Shinji Hagiwara
Yuichi Ishikawa
Hitoshi Kiyoi
Hidetoshi Murao
Toshiyuki Nakatani
Hayato OGURA
Koichi Saito
Takeshi Yamaura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujifilm Corp
Original Assignee
Fujifilm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujifilm Corp filed Critical Fujifilm Corp
Publication of AU2020229558A1 publication Critical patent/AU2020229558A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2020229558A 2019-02-28 2020-02-27 Combinational medication Abandoned AU2020229558A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019035668 2019-02-28
JP2019-035668 2019-02-28
PCT/JP2020/008063 WO2020175629A1 (ja) 2019-02-28 2020-02-27 組合せ医薬

Publications (1)

Publication Number Publication Date
AU2020229558A1 true AU2020229558A1 (en) 2021-09-23

Family

ID=72239685

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020229558A Abandoned AU2020229558A1 (en) 2019-02-28 2020-02-27 Combinational medication

Country Status (8)

Country Link
US (1) US20210386768A1 (https=)
EP (1) EP3932429A4 (https=)
JP (1) JPWO2020175629A1 (https=)
CN (1) CN113490512A (https=)
AU (1) AU2020229558A1 (https=)
CA (1) CA3131852A1 (https=)
TW (1) TW202045174A (https=)
WO (1) WO2020175629A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3865133A4 (en) * 2018-10-12 2021-11-10 FUJIFILM Corporation ANTITUMOR AGENTS FOR ACUTE MYELOID LEUKEMIA

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023027966A1 (en) 2021-08-24 2023-03-02 Biomea Fusion, Inc. Pyrazine compounds as irreversible inhibitors of flt3
TW202340177A (zh) 2021-12-30 2023-10-16 美商拜歐米富士恩股份有限公司 作為 flt3抑制劑之吡嗪化合物
WO2023225005A1 (en) 2022-05-17 2023-11-23 Biomea Fusion, Inc. Flt3 combination therapy for cancer and compositions therefor
WO2025012029A1 (en) * 2023-07-11 2025-01-16 Nerviano Medical Sciences S.R.L. Therapeutic combination comprising 4-(4-methyl-piperazin-1-yl)-n-{6-[2-(4-trifluoromethyl-benzyloxy)-ethoxy]-1h-indazol-3-yl}-benzamide and an antineoplastic agent

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
CN102438588B (zh) 2009-03-23 2015-04-01 埃姆比特生物科学公司 使用联合治疗法治疗疾病的方法
PT2840080T (pt) 2012-04-17 2018-02-06 Fujifilm Corp Composto heterocíclico que contém azoto ou sal do mesmo
CN105683167B (zh) 2013-10-16 2018-10-23 富士胶片株式会社 含氮杂环化合物的盐或其结晶、药品组合物及flt3抑制剂
WO2016027904A1 (ja) 2014-08-22 2016-02-25 富士フイルム株式会社 Ｆｌｔ３変異陽性癌を処置するための医薬組成物、変異型ｆｌｔ３阻害剤およびそれらの応用
JP6412471B2 (ja) 2015-07-15 2018-10-24 富士フイルム株式会社 含窒素複素環化合物の製造方法およびその中間体
TW202027749A (zh) * 2018-10-12 2020-08-01 日商富士軟片股份有限公司 急性骨髓性白血病用抗腫瘤劑

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3865133A4 (en) * 2018-10-12 2021-11-10 FUJIFILM Corporation ANTITUMOR AGENTS FOR ACUTE MYELOID LEUKEMIA

Also Published As

Publication number Publication date
WO2020175629A1 (ja) 2020-09-03
US20210386768A1 (en) 2021-12-16
EP3932429A4 (en) 2022-05-11
EP3932429A1 (en) 2022-01-05
CN113490512A (zh) 2021-10-08
JPWO2020175629A1 (https=) 2020-09-03
TW202045174A (zh) 2020-12-16
CA3131852A1 (en) 2020-09-03

Similar Documents

Publication Publication Date Title
AU2020229558A1 (en) Combinational medication
JP6849711B2 (ja) Ｋｒａｓ ｇ１２ｃの共有結合性阻害剤
EP2693881B1 (en) Substituted n-phenylpyrimidin-2-amine analogs as inhibitors of the axl kinase
AU2012245387C1 (en) Substituted Diaminocarboxamide and Diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
EP2739618B1 (en) Quinazoline compounds as serine/threonine kinase inhibitors
US20040242596A1 (en) Bicyclicpyrimidones and their use to treat diseases
TW200418837A (en) Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders
US10233160B2 (en) Substituted pyrido[3,4-d]pyrimidines and pyrido[4,3-d]pyrimidines as p70S6K inhibitors
AU2015288381B2 (en) Substituted 2-thioxo-imidazolidin-4-ones and spiro analogues thereof, active anti-cancer ingredient, pharmaceutical composition, medicinal preparation, method for treating prostate cancer
US10875863B2 (en) RIPK2 inhibitors and method of treating cancer with same
US20210220355A1 (en) Antitumor agent for acute myeloid leukemia
CN116113406B (zh) Gas41抑制剂及其使用方法
US9434714B2 (en) Pyrimidine imidazole amines as modulators of kinase activity
HK40057625A (en) Combinational medication
US9371311B2 (en) Benzoimidazol-2-yl pyrimidine derivatives
EP4731631A1 (en) Benzamidazole diazapinone parp inhibitors and methods of use
HK1239664A1 (en) Triazolopyrimidine compounds and uses thereof
HK1239664B (en) Triazolopyrimidine compounds and uses thereof
HK1195219B (en) Substituted n-phenylpyrimidin-2-amine analogs as inhibitors of the axl kinase
HK1195219A (en) Substituted n-phenylpyrimidin-2-amine analogs as inhibitors of the axl kinase
AU2015201030A1 (en) Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
HK40023268A (en) Substituted n-phenylpyrimidin-2-amine analogs as inhibitors of the axl kinase
BRPI0719333A2 (pt) Midazotriazinas e imidazopirimidinas como inbidores de cinase

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted